Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 241

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1

Open access
Obiorah, Ifeyinwa Emmanuela, Patel, Bhavisha A., Groarke, Emma M., Wang, Weixin, Trick, Megan, Ombrello, Amanda K., Ferrada, Marcela A., Wu, Zhijie, Gutierrez-Rodrigues, Fernanda, Lotter, Jennifer, Wilson, Lorena, Hoffmann, Patrycja, Cardona, Daniela Ospina, Patel, Nisha, Dulau-Florea, Alina, Kastner, Daniel L., Grayson, Peter C., Beck, David B., Young, Neal S., Calvo, Katherine R. · 2021 · Blood Advances

Abstract

Somatic mutations in UBA1 involving hematopoietic stem and myeloid cells have been reported in patients with the newly defined VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome. Here, we report clinical hematologic manifestations and unique bone marrow (BM) features in 16 patients with VEXAS. All patients were male and had a history of severe autoinflammatory and rheumatologic manifestations and a somatic UBA1 mutation (p.Met41). Ten patients had hematologic disorders: myelodysplastic syndrome (MDS; 6 of 16), multiple myeloma (2 of 16), monoclonal gammopathy of undetermined significance (2 of 16), and monoclonal B-cell lymphocytosis (2 of 16), and a few of those patients had 2 co-existing clonal processes. Although macrocytic anemia (100%) and lymphopenia (80%) were prevalent in all patients with VEXAS, thrombocytopenia and neutropenia were more common in patients with progression to MDS. All BMs in VEXAS patients had prominent cytoplasmic vacuoles in myeloid and erythroid precursors. In addition, most BMs were hypercellular with myeloid hyperplasia, erythroid hypoplasia, and varying degrees of dysplasia. All patients diagnosed with MDS were lower risk (low blast count, very good to intermediate cytogenetics) according to standard prognostic scoring with no known progression to leukemia. In addition, 10 of 16 patients had thrombotic events, including venous thromboembolism and arterial stroke. Although VEXAS presents symptomatically as a rheumatologic disease, morbidity and mortality are associated with progression to hematologic disease. Given the increased risk of developing MDS and multiple myeloma, surveillance for disease progression is important.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/bloodadvances.2021004976

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 241

Metadata

Authors
Obiorah, I. E., Patel, B. A., Groarke, E. M., Wang, W., Trick, M., Ombrello, A. K., Ferrada, M. A., Wu, Z., Gutierrez-Rodrigues, F., Lotter, J., Wilson, L., Hoffmann, P., Cardona, D. O., Patel, N., Dulau-Florea, A., Kastner, D. L., Grayson, P. C., Beck, D. B., Young, N. S., & Calvo, K. R.
Venue
Blood Advances
Published
2021-08-24
Volume
5
Issue
16
Pages
3203-3215
ISSN
  • 2473-9529 (ISSN-L)
  • 2473-9537
OpenAlex
W3195291942
Cited by
241
References
6
FWCI
22.07
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1. https://app.cochat.ai/papers/10.1182/bloodadvances.2021004976
The paper
Obiorah, I. E., Patel, B. A., Groarke, E. M., Wang, W., Trick, M., Ombrello, A. K., Ferrada, M. A., Wu, Z., Gutierrez-Rodrigues, F., Lotter, J., Wilson, L., Hoffmann, P., Cardona, D. O., Patel, N., Dulau-Florea, A., Kastner, D. L., Grayson, P. C., Beck, D. B., Young, N. S., & Calvo, K. R. (2021). Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1. Blood Advances. https://doi.org/10.1182/bloodadvances.2021004976

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.